Literature DB >> 29506994

Harnessing the Power of Proteomics to Assess Drug Safety and Guide Clinical Trials.

Maggie P Y Lam1, Ying Ge2.   

Abstract

Entities:  

Keywords:  Editorials; biomarkers; clinical trials; drugs; proteomics

Mesh：

Substances：

Year:  2018        PMID： 29506994      PMCID： PMC5842814          DOI： 10.1161/CIRCULATIONAHA.117.032876

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  9 in total

1.  Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease.

Authors:  Peter Ganz; Bettina Heidecker; Kristian Hveem; Christian Jonasson; Shintaro Kato; Mark R Segal; David G Sterling; Stephen A Williams
Journal:  JAMA       Date:  2016-06-21       Impact factor: 56.272

2.  Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease.

Authors:  Paolo Zanoni; Sumeet A Khetarpal; Daniel B Larach; William F Hancock-Cerutti; John S Millar; Marina Cuchel; Stephanie DerOhannessian; Anatol Kontush; Praveen Surendran; Danish Saleheen; Stella Trompet; J Wouter Jukema; Anton De Craen; Panos Deloukas; Naveed Sattar; Ian Ford; Chris Packard; Abdullah al Shafi Majumder; Dewan S Alam; Emanuele Di Angelantonio; Goncalo Abecasis; Rajiv Chowdhury; Jeanette Erdmann; Børge G Nordestgaard; Sune F Nielsen; Anne Tybjærg-Hansen; Ruth Frikke Schmidt; Kari Kuulasmaa; Dajiang J Liu; Markus Perola; Stefan Blankenberg; Veikko Salomaa; Satu Männistö; Philippe Amouyel; Dominique Arveiler; Jean Ferrieres; Martina Müller-Nurasyid; Marco Ferrario; Frank Kee; Cristen J Willer; Nilesh Samani; Heribert Schunkert; Adam S Butterworth; Joanna M M Howson; Gina M Peloso; Nathan O Stitziel; John Danesh; Sekar Kathiresan; Daniel J Rader
Journal:  Science       Date:  2016-03-11       Impact factor: 47.728

3.  Aptamer-Based Proteomic Profiling Reveals Novel Candidate Biomarkers and Pathways in Cardiovascular Disease.

Authors:  Debby Ngo; Sumita Sinha; Dongxiao Shen; Eric W Kuhn; Michelle J Keyes; Xu Shi; Mark D Benson; John F O'Sullivan; Hasmik Keshishian; Laurie A Farrell; Michael A Fifer; Ramachandran S Vasan; Marc S Sabatine; Martin G Larson; Steven A Carr; Thomas J Wang; Robert E Gerszten
Journal:  Circulation       Date:  2016-07-26       Impact factor: 29.690

Review 4.  Trials and Tribulations of CETP Inhibitors.

Authors:  Alan R Tall; Daniel J Rader
Journal:  Circ Res       Date:  2017-10-10       Impact factor: 17.367

5.  Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.

Authors:  Menno Vergeer; Michiel L Bots; Sander I van Leuven; Dick C Basart; Eric J Sijbrands; Gregory W Evans; Diederick E Grobbee; Frank L Visseren; Anton F Stalenhoef; Erik S Stroes; John J P Kastelein
Journal:  Circulation       Date:  2008-11-24       Impact factor: 29.690

6.  Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone.

Authors:  M J Forrest; D Bloomfield; R J Briscoe; P N Brown; A-M Cumiskey; J Ehrhart; J C Hershey; W J Keller; X Ma; H E McPherson; E Messina; L B Peterson; W Sharif-Rodriguez; P K S Siegl; P J Sinclair; C P Sparrow; A S Stevenson; S-Y Sun; C Tsai; H Vargas; M Walker; S H West; V White; R F Woltmann
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

7.  Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy.

Authors:  Yetrib Hathout; Edward Brody; Paula R Clemens; Linda Cripe; Robert Kirk DeLisle; Pat Furlong; Heather Gordish-Dressman; Lauren Hache; Erik Henricson; Eric P Hoffman; Yvonne Monique Kobayashi; Angela Lorts; Jean K Mah; Craig McDonald; Bob Mehler; Sally Nelson; Malti Nikrad; Britta Singer; Fintan Steele; David Sterling; H Lee Sweeney; Steve Williams; Larry Gold
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-26       Impact factor: 11.205

8.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study.

Authors:  Benjamin F Voight; Gina M Peloso; Marju Orho-Melander; Ruth Frikke-Schmidt; Maja Barbalic; Majken K Jensen; George Hindy; Hilma Hólm; Eric L Ding; Toby Johnson; Heribert Schunkert; Nilesh J Samani; Robert Clarke; Jemma C Hopewell; John F Thompson; Mingyao Li; Gudmar Thorleifsson; Christopher Newton-Cheh; Kiran Musunuru; James P Pirruccello; Danish Saleheen; Li Chen; Alexandre F R Stewart; Arne Schillert; Unnur Thorsteinsdottir; Gudmundur Thorgeirsson; Sonia Anand; James C Engert; Thomas Morgan; John Spertus; Monika Stoll; Klaus Berger; Nicola Martinelli; Domenico Girelli; Pascal P McKeown; Christopher C Patterson; Stephen E Epstein; Joseph Devaney; Mary-Susan Burnett; Vincent Mooser; Samuli Ripatti; Ida Surakka; Markku S Nieminen; Juha Sinisalo; Marja-Liisa Lokki; Markus Perola; Aki Havulinna; Ulf de Faire; Bruna Gigante; Erik Ingelsson; Tanja Zeller; Philipp Wild; Paul I W de Bakker; Olaf H Klungel; Anke-Hilse Maitland-van der Zee; Bas J M Peters; Anthonius de Boer; Diederick E Grobbee; Pieter W Kamphuisen; Vera H M Deneer; Clara C Elbers; N Charlotte Onland-Moret; Marten H Hofker; Cisca Wijmenga; W M Monique Verschuren; Jolanda M A Boer; Yvonne T van der Schouw; Asif Rasheed; Philippe Frossard; Serkalem Demissie; Cristen Willer; Ron Do; Jose M Ordovas; Gonçalo R Abecasis; Michael Boehnke; Karen L Mohlke; Mark J Daly; Candace Guiducci; Noël P Burtt; Aarti Surti; Elena Gonzalez; Shaun Purcell; Stacey Gabriel; Jaume Marrugat; John Peden; Jeanette Erdmann; Patrick Diemert; Christina Willenborg; Inke R König; Marcus Fischer; Christian Hengstenberg; Andreas Ziegler; Ian Buysschaert; Diether Lambrechts; Frans Van de Werf; Keith A Fox; Nour Eddine El Mokhtari; Diana Rubin; Jürgen Schrezenmeir; Stefan Schreiber; Arne Schäfer; John Danesh; Stefan Blankenberg; Robert Roberts; Ruth McPherson; Hugh Watkins; Alistair S Hall; Kim Overvad; Eric Rimm; Eric Boerwinkle; Anne Tybjaerg-Hansen; L Adrienne Cupples; Muredach P Reilly; Olle Melander; Pier M Mannucci; Diego Ardissino; David Siscovick; Roberto Elosua; Kari Stefansson; Christopher J O'Donnell; Veikko Salomaa; Daniel J Rader; Leena Peltonen; Stephen M Schwartz; David Altshuler; Sekar Kathiresan
Journal:  Lancet       Date:  2012-05-17       Impact factor: 79.321

9.  Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.

Authors:  Stephen A Williams; Ashwin C Murthy; Robert K DeLisle; Craig Hyde; Anders Malarstig; Rachel Ostroff; Sophie J Weiss; Mark R Segal; Peter Ganz
Journal:  Circulation       Date:  2017-10-03       Impact factor: 29.690
  9 in total
  1 in total

1.  Considerations of biomarker application for cancer continuum in the era of precision medicine.

Authors:  Rayjean J Hung; Elham Khodayari Moez; Shana J Kim; Sanjeev Budhathoki; Jennifer D Brooks
Journal:  Curr Epidemiol Rep       Date:  2022-07-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.